Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2025

Garassino Marina Chiara, He Yong, Ahn Myung-Ju, Orlov Sergey V, Potter Vanessa, Kato Terufumi, Laskin Janessa, Voon Pei Jye, Reungwetwattana Thanyanan, Ramalingam Suresh S, Wu Yi-Long, Albayaty Muna, Cross Sarah L, Huang Xiangning, Kulkarni Dakshayini, Cho Byoung Chul

Abstract excerpt

INTRODUCTION: This post-hoc analysis of the registrational FLAURA study and AURA program reports long-term safety data in epidermal growth factor receptor-mutated (EGFRm), advanced non-small cell lung cancer (NSCLC) treated with osimertinib for ≥ 36 months. METHODS: Patients from FLAURA who received first-line osimertinib and from the AURA program (AURA, AURA2, AURA3) who received ≥ second-line osimertinib were...

Read the complete abstract on PubMed

Topics

Humans
Aniline Compounds
Acrylamides
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Female

Male

Aged

Middle Aged

ErbB Receptors

Mutation

Adult

Aged, 80 and over

Protein Kinase Inhibitors

Antineoplastic Agents

Treatment Outcome

Indoles

Pyrimidines

Source

Identifiers

PMID: 40056874
DOI: 10.1016/j.lungcan.2025.108417

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.PMID 40056874Read ↗

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.Semantic proximity Read ↗

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.Semantic proximity Read ↗

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.Semantic proximity Read ↗

Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study.Semantic proximity Read ↗

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).Semantic proximity Read ↗

Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.Semantic proximity Read ↗

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.Semantic proximity Read ↗

Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.